Prevalence and spectrum of germline cancer susceptibility gene mutations among patients with early-onset colorectal cancer

JAMA Oncology

Volumn 3, Issue 4, 2017, Pages 464-471

  Pearlman, Rachel ^a   Frankel, Wendy L ^b   Swanson, Benjamin ^b   Zhao, Weiqiang ^b   Yilmaz, Ahmet ^b   Miller, Kristin ^b   Bacher, Jason ^b   Bigley, Christopher ^a   Nelsen, Lori ^a   Goodfellow, Paul J ^a   Goldberg, Richard M ^a   Paskett, Electra ^a   Shields, Peter G ^a   Freudenheim, Jo L ^c   Stanich, Peter P ^b   Lattimer, Ilene ^a   Arnold, Mark ^b   Liyanarachchi, Sandya ^a   Kalady, Matthew ^d   Heald, Brandie ^d   Greenwood, Carla ^d   Paquette, Ian ^e   Prues, Marla ^f   Draper, David J ^g   Lindeman, Carolyn ^g   Kuebler, J Philip ^h   Reynolds, Kelly ⁱ   Brell, Joanna M ^j   Shaper, Amy A ^j   Mahesh, Sameer ^k   Buie, Nicole ^k   Weeman, Kisa ^l   Shine, Kristin ^l   Haut, Mitchell ^m   Edwards, Joan ^m   Bastola, Shyamal ⁿ   Wickham, Karen ⁿ   Khanduja, Karamjit S ^o   Zacks, Rosemary ^o   Pritchard, Colin C ^p   Shirts, Brian H ^p   Jacobson, Angela ^p   Allen, Brian ^q   De La Chapelle, Albert ^a   Hampel, Heather ^a   more..

^a OHIO STATE UNIVERSITY   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^f CHRIST HOSPITAL   (United States)

^g GOOD SAMARITAN HOSPITAL   (United States)

^h Department of Pharmacy   (United States)

ⁱ RIVERSIDE METHODIST HOSPITAL   (United States)

^j METROHEALTH MEDICAL CENTER   (United States)

^k AKRON CITY HOSPITAL   (United States)

^l AULTMAN HOSPITAL   (United States)

^m Mercy Medical Center   (United States)

ⁿ Genesis Healthcare System   (United States)

^o Mount Carmel East Hospital   (United States)

^p UNIVERSITY OF WASHINGTON   (United States)

^q Myriad Genetic Laboratories   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; COLORECTAL TUMOR; DNA MICROARRAY; GENETIC PREDISPOSITION; GENETICS; GERMLINE MUTATION; HUMAN; MIDDLE AGED; NEOPLASTIC SYNDROMES, HEREDITARY; ONSET AGE; PREVALENCE;

ADULT; AGE OF ONSET; COLORECTAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; GERM-LINE MUTATION; HUMANS; MIDDLE AGED; NEOPLASTIC SYNDROMES, HEREDITARY; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREVALENCE;

EID: 85018592899     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.5194     Document Type: Article

References (27)

1. American Cancer Society. Colorectal Cancer Facts & Figures. 2016. http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf. Accessed July 15, 2016.
2. Barnetson RA, Tenesa A, Farrington SM, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med. 2006;354(26):2751-2763.
3. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26(35):5783-5788.
4. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005;352(18):1851-1860.
5. Mork ME, You YN, Ying J, et al. High prevalence of hereditary cancer syndromes in adolescents and young adults with colorectal cancer. J Clin Oncol. 2015;33(31):3544-3549.
6. Yurgelun MB, Allen B, Kaldate RR, et al Identification of a variety of mutations in cancer predisposition genes in patients with suspected Lynch syndrome. Gastroenterology. 2015;149(3):604-613.e620.
7. Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: genetic testing strategies in newly diagnosed individuals with colorectal cancer aimed at reducing morbidity and mortality from Lynch syndrome in relatives. Genet Med. 2009;11(1):35-41.
8. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genet Med. 2009;11(1):42-65.
9. National Cancer Care Network. Referenced with permission from the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal V.1.2016 National Comprehensive Cancer Network IArrAJ. https://www.nccn.org/professionals/physician-gls/f-guidelines.asp#detection. Accessed November 17, 2016.
10. Gallego CJ, Shirts BH, Bennette CS, et al. Next-generation sequencing panels for the diagnosis of colorectal cancer and polyposis syndromes: a cost-effectiveness analysis. J Clin Oncol. 2015;33(18):2084-2091.
11. Ohio Department of Health. Ohio Cancer Incidence Surveillance System (OCISS). https://www.odh.ohio.gov/healthstats/ocisshs/ci-surv1.aspx. Accessed November 28, 2016.
12. Buckingham L, Flaws ML. Molecular Diagnostics Fundamentals, Methods, & Clinical Applications. Philadelphia, PA: F. A. Davis Co; 2007:65-79.
13. Shia J, Tang LH, Vakiani E, et al. Immunohistochemistry as first-line screening for detecting colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: a 2-antibody panel may be as predictive as a 4-antibody panel. Am J Surg Pathol. 2009;33(11):1639-1645.
14. Newton K, Jorgensen NM, Wallace AJ, et al. Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch syndrome (HNPCC). J Med Genet. 2014;51(12):789-796.
15. Pritchard CC, Smith C, Salipante SJ, et al. ColoSeq provides comprehensive lynch and polyposis syndrome mutational analysis using massively parallel sequencing. J Mol Diagn. 2012;14(4):357-366.
16. Nord AS, Lee M, King MC, Walsh T. Accurate and exact CNV identification from targeted high-throughput sequence data. BMC Genomics. 2011;12:184.
17. Judkins T, Leclair B, Bowles K, et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes the BRCA1 and BRCA2 genes to assess hereditary cancer risk. BMC Cancer. 2015;15:215.
18. Richards S, Aziz N, Bale S, et al; ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-424.
19. Shirts BH, Casadei S, Jacobson AL, et al. Improving performance of multigene panels for genomic analysis of cancer predisposition. Genet Med. 2016;(Feb):4.
20. Haraldsdottir S, Hampel H, Tomsic J, et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations. Gastroenterology. 2014;147(6):1308-1316.e1.
21. Boursi B, Sella T, Liberman E, et al. The APC p.I1307K polymorphism is a significant risk factor for CRC in average risk Ashkenazi Jews. Eur J Cancer. 2013;49(17):3680-3685.
22. Laken SJ, Petersen GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet. 1997;17(1):79-83.
23. Liang J, Lin C, Hu F, et al. APC polymorphisms and the risk of colorectal neoplasia: a HuGE review and meta-analysis. Am J Epidemiol. 2013;177(11):1169-1179.
24. Goyal G, Fan T, Silberstein PT. Hereditary cancer syndromes: utilizing DNA repair deficiency as therapeutic target. Fam Cancer. 2016;15(3):359-366.
25. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509-2520.
26. Phelan CM, Iqbal J, Lynch HT, et al; Hereditary Breast Cancer Study Group. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. Br J Cancer. 2014;110(2):530-534.
27. Garre P, Martín L, Sanz J, et al. BRCA2 gene: a candidate for clinical testing in familial colorectal cancer type X. Clin Genet. 2015;87(6):582-587.